Horizon Investment Services LLC Acquires 24,724 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Horizon Investment Services LLC increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 167.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,524 shares of the biopharmaceutical company’s stock after buying an additional 24,724 shares during the period. Horizon Investment Services LLC’s holdings in Catalyst Pharmaceuticals were worth $825,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of CPRX. abrdn plc purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter worth about $10,115,000. Vanguard Group Inc. grew its holdings in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock valued at $175,957,000 after buying an additional 390,116 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $6,887,000. JPMorgan Chase & Co. lifted its holdings in shares of Catalyst Pharmaceuticals by 80.3% in the fourth quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company’s stock worth $15,364,000 after buying an additional 327,936 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in Catalyst Pharmaceuticals by 74.3% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock valued at $15,421,000 after acquiring an additional 312,000 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on CPRX. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Bank of America reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens restated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $32.29.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $24.69 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 3.31 and a beta of 0.84. The firm has a 50 day moving average price of $22.66 and a 200-day moving average price of $21.80.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.